Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
IMNM Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 15, 2026
Report Source: 2026 1st Quarter Report
Immunome Inc. Stock Analysis IMNM
United States Health Care Mid Cap Report: Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Bothell, Washington and currently employs 117 full-time employees. The company went IPO on 2020-10-02. The firm is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The firm's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Read More Immunome Inc (IMNM) Chart
Key Statistics of Immunome Inc (IMNM)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$19.02Volume
2.18MP/E Ratio (TTM)
-52 Week Range
Market Cap
2.60BAvg. Volume
1.43MDividend Yield
-Financial Metrics & Statements of Immunome Inc (IMNM)
FAQ's for Immunome Inc (IMNM)
- According to Musaffa’s Shariah screening methodology, Immunome Inc (IMNM) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Immunome Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Immunome Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Immunome Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Immunome Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Immunome Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.